Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Future Oncology (London, England)
|
March 31, 2021
Antibody-radiation conjugates for acute myeloid leukemia: an interview with Mark Berger
Mark S Berger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2012
Like raising a child
Mark S Berger
Clinical Lymphoma
|
April 24, 2002
Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia
Lance H Leopold, Mark S Berger, Jay Feingold
Clinical Lung Cancer
|
December 12, 2025
Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC
Alexander I Spira, David Berz, Robert M Jotte, et al.
Investigational New Drugs
|
November 27, 2002
Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse
Mark S Berger, Lance H Leopold, James A Dowell, et al.
Oncotarget
|
October 16, 2020
Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy
Wojciech Dawicki, Kevin J H Allen, Ravendra Garg, et al.
Clinical Advances in Hematology & Oncology : H&O
|
October 15, 2005
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse
Lance H Leopold, Mark S Berger, Su-Chun Cheng, et al.
Oncoimmunology
|
August 16, 2019
Daratumumab-<sup>225</sup>Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
Wojciech Dawicki, Kevin J H Allen, Rubin Jiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2010
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
Jimmy J Hwang, John Kuruvilla, David Mendelson, et al.
Cancer Immunology, Immunotherapy : CII
|
April 2, 2003
A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma
Stephen Y Chan, Alan N Gordon, Robert E Coleman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Future Oncology (London, England)
|
March 31, 2021
Antibody-radiation conjugates for acute myeloid leukemia: an interview with Mark Berger
Mark S Berger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2012
Like raising a child
Mark S Berger
Clinical Lymphoma
|
April 24, 2002
Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia
Lance H Leopold, Mark S Berger, Jay Feingold
Clinical Lung Cancer
|
December 12, 2025
Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC
Alexander I Spira, David Berz, Robert M Jotte, et al.
Investigational New Drugs
|
November 27, 2002
Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse
Mark S Berger, Lance H Leopold, James A Dowell, et al.
Oncotarget
|
October 16, 2020
Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy
Wojciech Dawicki, Kevin J H Allen, Ravendra Garg, et al.
Clinical Advances in Hematology & Oncology : H&O
|
October 15, 2005
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse
Lance H Leopold, Mark S Berger, Su-Chun Cheng, et al.
Oncoimmunology
|
August 16, 2019
Daratumumab-<sup>225</sup>Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
Wojciech Dawicki, Kevin J H Allen, Rubin Jiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2010
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
Jimmy J Hwang, John Kuruvilla, David Mendelson, et al.
Cancer Immunology, Immunotherapy : CII
|
April 2, 2003
A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma
Stephen Y Chan, Alan N Gordon, Robert E Coleman, et al.
Page
of 2